Cardiac troponin I: the gold standard in acute myocardial infarction diagnosis

Hasić, Sabaheta; Kiseljaković, Emina; Jadrić, Radivoj; Radovanović, Jovan; Winterhalter-Jadrić, Mira

doi:10.17305/bjbms.2003.3527

Cited by 29 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, cardiac troponins are considered the 'gold standard' for acute MI diagnosis [47]. Currently, cardiac troponins are considered the 'gold standard' for acute MI diagnosis [47].…”

Section: Potential Value Of Mirnas As Clinical Biomarkerssupporting

confidence: 87%

miRNAs in post-ischaemic angiogenesis and vascular remodelling

Saif

Emanueli

2014

Biochemical Society Transactions

View full text Add to dashboard Cite

miRNAs are highly conserved non-coding RNA molecules that negatively control gene expression by binding to target mRNAs promoting their degradation. A multitude of miRNAs have been reported to be involved in angiogenesis and vascular remodelling. In the present review, we aim to describe the effect of miRNAs in post-ischaemic repair. First, we describe the miRNAs reported in ischaemic diseases and in angiogenesis. Then we examine their capacity to modulate the behaviour of stem and progenitor cells which could be utilized for vascular repair. And finally we discuss the potential of miRNAs as new clinical biomarkers and therapeutic targets.

show abstract

“…Currently, cardiac troponins are considered the 'gold standard' for acute MI diagnosis [47]. Currently, cardiac troponins are considered the 'gold standard' for acute MI diagnosis [47].…”

Section: Potential Value Of Mirnas As Clinical Biomarkerssupporting

confidence: 87%

miRNAs in post-ischaemic angiogenesis and vascular remodelling

Saif

Emanueli

2014

Biochemical Society Transactions

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] Although myocardial infarction is uncommon in veterinary medicine, some dogs and cats with conditions involving myocardial damage, such as hypertrophic cardiomyopathy, unclassified cardiomyopathy, dilated cardiomyopathy, subaortic stenosis, mitral valve degeneration, gastric dilatation-volvulus, blunt thoracic trauma, and babesiosis have been found to have high cTnI concentrations. [7][8][9][10][11][12] Cardiac troponin I analyzers have not been standardized and because each company can use a potentially different and proprietary target amino acid in the assay, values obtained on 1 analyzer may not be directly comparable to values obtained on a different analyzer.…”

mentioning

confidence: 99%

Comparison of Canine Cardiac Troponin I Concentrations as Determined by 3 Analyzers

Adin

Oyama

Sleeper

et al. 2006

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Recent interest in cardiac biomarkers has led to the validation of several commercial analyzers for cardiac troponin I (cTnI) evaluation in dogs; however, these analyzers have not been standardized.Hypothesis: It was hypothesized that canine plasma cTnI concentrations as determined by 3 different analyzers would be similar.Animals: Twenty-three dogs with cardiac disease were studied. Methods: Reconstituted purified canine free cTnI was diluted with canine plasma to 8 concentrations (0.01, 0.1, 0.78, 1.56, 3.13, 6.25, 12.5, and 25 ng/mL), for analysis by 3 analyzers, the Biosite Triage Meter, the Dade-Behring Stratus, and the Beckman-Coulter Access AccuTnI. Plasma samples from 23 dogs with cardiac disease were also analyzed for cTnI concentrations on all analyzers.Results: Troponin I concentrations in sick dogs were ,0.05-5.72 ng/mL (Biosite), 0.02-11.1 ng/mL (Access), and 0.02-9.73 ng/mL (Stratus). Analyzer results were highly correlated with each other (r 5 0.97 to 1.0 for purified dilutions, r 5 0.61 to 0.89 for samples from dogs); however, the limits of agreement were wide for both purified dilutions and clinical samples. Recovery was highest for the Access (334-1467%) and lowest for the Biosite (38-60%); Stratus 52-233%. Analyzer variability was lowest for the Access (1.2-10.4%) and highest for the Stratus (4.8-33.6%); Biosite 2.8-16.5%.Conclusions and Clinical Importance: Results from this study suggest that although canine cTnI values obtained from the Biosite, Stratus, and Access analyzers are closely correlated, they cannot be directly compared with each other. In the absence of a gold standard none of the analyzers can be considered more correct than the others.

show abstract

“…Also, they require capturing the unusual signal and therefore, cannot be considered as early detection [ 119 ]. But detecting cTnI as a biomarker of AMI offers higher sensitivity, and selectivity [ 120 ]. Commonly used assays to detect this biomarker, including ELISA, fluorescence, electrochemiluminescence immunoassay, and surface plasmon resonance (SPR) are not cost-effective, and swift since they necessitate using highly sophisticated instruments and skilled laboratory personal [ 121 ].…”

Section: Selective Adhesion On Fet For Biosensing Applicationsmentioning

confidence: 99%

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Sadighbayan

Hasanzadeh

Ghafar-Zadeh

2020

TrAC Trends in Analytical Chemistry

184

View full text Add to dashboard Cite

The use of field-Effect-Transistor (FET) type biosensing arrangements has been highlighted by researchers in the field of early biomarker detection and drug screening. Their non-metalized gate dielectrics that are exposed to an electrolyte solution cover the semiconductor material and actively transduce the biological changes on the surface. The efficiency of these novel devices in detecting different biomolecular analytes in a real-time, highly precise, specific, and label-free manner has been validated by numerous research studies. Considerable progress has been attained in designing FET devices, especially for biomedical diagnosis and cell-based assays in the past few decades. The exceptional electronic properties, compactness, and scalability of these novel tools are very desirable for designing rapid, label-free, and mass detection of biomolecules. With the incorporation of nanotechnology, the performance of biosensors based on FET boosts significantly, particularly, employment of nanomaterials such as graphene, metal nanoparticles, single and multi-walled carbon nanotubes, nanorods, and nanowires. Besides, their commercial availability, and high-quality production on a large-scale, turn them to be one of the most preferred sensing and screening platforms. This review presents the basic structural setup and working principle of different types of FET devices. We also focused on the latest progression regarding the use of FET biosensors for the recognition of viruses such as, recently emerged COVID-19, Influenza, Hepatitis B Virus, protein biomarkers, nucleic acids, bacteria, cells, and various ions. Additionally, an outline of the development of FET sensors for investigations related to drug development and the cellular investigation is also presented. Some technical strategies for enhancing the sensitivity and selectivity of detection in these devices are addressed as well. However, there are still certain challenges which are remained unaddressed concerning the performance and clinical use of transistor-based point-of-care (POC) instruments; accordingly, expectations about their future improvement for biosensing and cellular studies are argued at the end of this review.

show abstract

Cardiac troponin I: the gold standard in acute myocardial infarction diagnosis

Cited by 29 publications

References 8 publications

miRNAs in post-ischaemic angiogenesis and vascular remodelling

miRNAs in post-ischaemic angiogenesis and vascular remodelling

Comparison of Canine Cardiac Troponin I Concentrations as Determined by 3 Analyzers

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Contact Info

Product

Resources

About